Nykode Therapeutics ASA · OSL:NYKD
Nykode Therapeutics ASA — Investor Presentation (March 2024)
78 slides from Nykode Therapeutics ASA's investor presentation, March 2024
Slide 1: Company Presentation
Company Presentation March 2024
Slide 2: Forward-looking statement
Forward-looking statement This announcement and any materials distributed in connection with this presentation may contain certain forward- looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumpt
Slide 3: Global leader in APC-targeted immunotherapy technology
Global leader in antigen presenting cell (APC)-targeted immunotherapy technology NYKODE THERAPEUTICS (NYKD-OL, MKT CAP ~$555M1) Differentiated immunotherapies targeting antigens to Antigen-Presenting Cell (APC) to direct tailor-made immune responses with focus on oncology and autoimmune diseases Onc
Slide 4: Nykode executive management
Nykode executive management Experienced and international management team MICHAEL ENGSIG AGNETE FREDRIKSEN MIKKEL W. PEDERSEN KLAUS EDVARDSEN HARALD GURVIN Chief Executive Officer Chief Business Officer & Chief Scientific Officer Chief Development Officer Chief Financial Officer Co-founder Nykode Th
Slide 5: Top-tier collaborations for cancer and infectious disease vaccines
Top-tier collaborations for cancer and infectious disease vaccines valued potentially more than $1.64 billion plus royalties Partner Collaboration Terms Clinical Development $925M~ Regeneron to develop and potentially Multi-target license and $30M upfront commercialize products collaboration agree
Slide 6: Broad pipeline targeting early to late-stage cancer treatment
Broad pipeline targeting early to late-stage cancer treatment Upcoming Asset Indication Rights Preclinical Phase 1 Phase 2 Phase 3 Catalyst Oncology 1 Initiate trial HPV16+ cervical cancer C-02, C-04 (Q1 2024) 2 Dose level VB10.16 HPV16+ head and neck cancer C-03 recommendation (H2 2024) 2 Off-the-s
Slide 7: Balanced portfolio designed to address all stages of disease
Balanced portfolio designed to adress all stages of disease from pre-malignant to late-stage cancer treatment Strategic expansion of vaccine candidate portfolio Recurrent and/or Metastatic Locally advanced Pre-Malignant Off-the-shelf C-02 HPV16+ Cervical C-05 C-01 Cancer C-04 VB10.16 HPV16+ C-03 SCC
Slide 8: Modular vaccine technology allows APC-targeting to direct immune responses
Modular vaccine technology allows APC-targeting to direct immune responses DNA plasmid Targeting unit to attract and bind APCs encoding Ability to tailor the targeting unit enables induction of different immune response Nykode vaccine profiles to specific diseases1 Dimerization unit for crosslinking
Slide 9: Cancer vaccine platform induces rapid, robust CD8 T cell response
Nykode’s cancer vaccine platform induces a rapid, robust and long-lasting CD8 T cell response against cancer cells MECHANISM OF ACTION – T CELL INDUCTION Nykode Therapeutics | Company Presentation - March 2023 9
Slide 10: Controlled cross-presentation induces broader and stronger CD8 responses
Controlled cross-presentation by specific APC receptor targeting induces broader & stronger CD8 responses than non-targeted technologies such as mRNA- and peptide vaccines Comparison with peptide and RNA vaccination strategies shows broader CD8 Addition of strong CD8 responses to epitopes and CD4 re
Slide 11: VB10.16 in HPV16+ cancers
VB10.16 in HPV16+ cancers Nykode Therapeutics | Company Presentation - March 2023 11
Slide 12: VB10.16: Therapeutic vaccine candidate for HPV16+ cancers
VB10.16: Therapeutic vaccine candidate for HPV16+ cancers Targeting unit Off-the-shelf therapeutic cancer DNA vaccine CCL3L1 against HPV16 induced malignancies HPV16 is the most prevalent oncogenic HPV strain VB10.16 Off-the-shelf vaccine Targeting the cancer-specific full-length HPV16 E7 target
Slide 13: HPV16+ cervical cancer is a significant unmet need
HPV16+ cervical cancer is a significant unmet need Cervical cancer incidence worldwide ~130,000 new HPV16+ cancer cases per year • 4th most common cancer in (U.S. and Europe1) women worldwide • 4th leading cause of cancer- 23% related death • Prognosis is poor for recurrent and/or metastatic Anal/Vu
Slide 14: HPV+ cancer incidence is expected to increase
HPV+ cancer incidence is expected to increase despite prophylactic HPV vaccination U.S. + EU5 + China + Japan HPV+ CERVICAL CANCER HPV+ HNSCC DIAGNOSED INCIDENT CASES1 DIAGNOSED INCIDENT CASES2 +74% 222,412 163,982 +65% 128,051 112,081 99,250 67,794 2010 2020 2030 2010 2020 2030 1 GlobalData Cervica
Slide 15: VB C-02: VB10.16 plus atezolizumab in advanced cervical cancer
VB C-02: VB10.16 plus atezolizumab (Tecentriq®) in advanced cervical cancer A Multi-Centre, Single Arm, Open-label Phase 2a Trial of the Combination of VB10.16 and atezolizumab in Patients with Advanced or Recurrent, Non-resectable HPV16 Positive Cervical Cancer (NCT04405349) Objectives: Safety/to
Slide 16: Recent progress increased survival, but room for improvement remains
Recent clinical progress has increased survival outcomes in advanced cervical cancer patients, but room for significant improvement remains Patients that have failed 1 or more line of systemic treatment have limited Progression Free Survival and Overall Survival with current approved treatments Sign
Slide 17: VB10.16 evaluated in pretreated advanced cervical cancer patients
VB10.16 evaluated in pretreated advanced cervical cancer patients, with ~40% PD-L1 negative Baseline characteristics PATIENT CHARACTERISTICS1 SAF2 (n = 52) Median age, years (range) 47.5 (27-83) Histology Squamous cell carcinoma 81% (42/52) Adenocarcinoma 15% (8/52) Adenosquamous carcinoma 2%
Slide 18: VB10.16 was generally well-tolerated
VB10.16 was generally well-tolerated VB10.16 plus atezolizumab tolerability profile was consistent with checkpoint inhibitor monotherapy1 Treatment-related Adverse Events assessed as related to VB10.16 VB10.16 in combination with atezolizumab was generally (n = 52) well-tolerated and showed a favour
Slide 19: Strong anti-tumor effect leading to prolonged overall survival
Strong anti-tumor effect leading to prolonged overall survival (compared to CPI alone)1 High mOS of >25 months (not reached) and mPFS 6.3 months in PD-L1+ patients Endpoint All patients2 PD-L1+ 3 Value 95% CI Value 95% CI Strong and durable anti-tumor efficacy ORR 19% (9%-33%) 29% (13%-51%) across
Slide 20: VB10.16 C-02 data compare strongly to CPI monotherapy and SoC
VB10.16 C-02 data compare strongly to CPI monotherapy as well as expected SoC in ≥2L r/m cervical cancer CPI Monotherapy in r/m CC VB10.16 plus Atezolizumab in Pembrolizumab Cemiplimab in Tisotumab vedotin atezolizumab PD-L1+††† in PD-L1+** PD-L1+ †† (PD-L1 agnostic) ‡ ‡ in PD-L1+ Skyscraper-04, Emp
Slide 21: VB10.16 coupled with CPI led to lasting responses
VB10.16 coupled with CPI led to lasting responses All (n = 47) By PD-L1 status (n = 40) Note: 7 out of 47 responders had PD-L1 unknown status, 40 out of 47 had known PD-L1 status Nykode Therapeutics | Company Presentation - March 2023 21
Slide 22: VB10.16 led to prolonged overall survival
VB10.16 led to prolonged overall survival in advanced cervical cancer patients Median overall survival of 16.9 months in overall population, mOS not reached (> 25 months) in PD-L1+ patients Overall survival Overall survival (PD-L1+ vs. PD-L1-) mOS N.R. (> 25 months) mOS 16.9 months mOS 7.3 months No
Slide 23: VB10.16 induced HPV16-specific T cell responses correlated with response
VB10.16 induced HPV16-specific T cell responses that are significantly correlated with clinical response HIGHER FOLD INCREASED T CELL HIGHER PEAK T CELL RESPONSES IN RESPONSES IN PATIENTS WITH DISEASE PATIENTS WITH DISEASE CONTROL CONTROL 1500 p=0.0113 50 p=0.0346 1000 500 250 SFU/106 PBMC 10 Fold c
Slide 24: HPV16 ctDNA dynamics associated with clinical response
HPV16 circulating tumor DNA dynamics is associated with clinical response ALL PATIENTS WITH CLINICAL RESPONSE PER RECIST 1.1 EARLY CTDNA DYNAMICS (WEEK 9-11) ASSOCIATED WITH HAVE MOLECULAR RESPONSE IMPROVED CLINICAL OUTCOME DCR PD Increase Decrease Disease control N=16 5 (31%) 11 (69%) All patients
Slide 25: T cell responses remain strong and long-lasting
T cell responses remain strong and long-lasting T cell clonotype analysis EXPANSION OF NOVEL AND EXPANDED RAPID AND PERSISTENT EXPANSION OF T CELL CLONES CLONES ON TREATMENT • Novel expanded clones constituted a median of • Rapid and persistent on-treatment T cell expansion 0.66% of the peripheral T
Slide 26: Patient case: longitudinal T cell clonal expansion
Patient case: longitudinal T cell clonal expansion Persistent expansion of novel and pre-existing clones throughout the treatment FREQUENCY OF EXPANDED CLONOTYPES NUMBER OF EXPANDED CLONES A persistent expansion of Pre-exising expanded novel and pre-existing Novel clones throughout the treatment p
Slide 27: C-02 data supports patient selection for registrational study
C-02 data supports patient population selection for potentially registrational study Clinical activity observed across all endpoints, with strongest results in PD-L1+ patients with 1 prior line of systemic therapy Duration of response data in PD-L1+ patients show potential for competitive positi
Slide 28: Maximizing addressable patient populations
Maximizing addressable patient populations by diversifying offerings and broadening therapeutic scope Building a cancer vaccine franchise following strong clinical validation Validation Today Future Opportunities C-05 Adjuvant Settings Move earlier to expand patient population and Indication Expansi
Slide 29: Creating a portfolio of targeted vaccines for HPV16+ cancers
Creating a portfolio of targeted vaccines for HPV16+ cancers VB10.16 portfolio C-02 C-03 C-04 C-05 r/m head and neck cancer r/m Cervical Cancer, ≥2L r/m Cervical Cancer, Locally Advanced Cervical Indication (HNSCC), PD-L1+, 2L Cancer (LACC) PD-L1+, 1L Up to 9 mg in combination 3 mg in combination wi
Slide 30: VB-C-04 trial in advanced HPV16-positive cervical cancer
VB-C-04 trial in advanced HPV16-positive cervical cancer Randomized Phase 2 selection trial in recurrent cervical cancer progressing on 1st line SOC (pembrolizumab + chemotherapy +/- bevacizumab) ♦ Dosing schedule VB10.16 vaccine (i.m.) ♦ Key eligibility criteria ♦ Q3W for 5 cycles (induction period
Slide 31: VB-C-04 VB10.16+atezolizumab or placebo in 2L recurrent CC
VB-C-04 VB10.16+atezolizumab or placebo in 2L recurrent CC Overview: randomized Phase 2 selection design Part 1 Part 2 a) b) Arm A: Enroll Final analysis ( n = 100) VB10.16 + another 70 atezolizumab pts in Interim for futility recurrant (stage IVB) CC (n = 60) (n = 30) superior arm • HPV-16+ • PD-L1
Slide 32: Locally advanced cervical cancer represents a new opportunity
Locally advanced cervical cancer represents a new opportunity for immunotherapy Press release Nykode Therapeutics | Company Presentation - March 2023 32
Slide 33: VB C-05: VB10.16+CPI in Locally Advanced Cervical Cancer
VB C-05: VB10.16+CPI as concurrent treatment to CRT in Locally Advanced Cervical Cancer Randomized Phase 2 PoC trial in a HPV16+ LACC setting Concurrent Adjuvant HPV 16+ High-risk locally advanced cervical cancer CRT + CPI + CPI + Primary endpoint (FIGO 2018) defined as VB10.16 VB10.16 PFS and OS st
Slide 34: NYK011: Vaccine aimed at reducing burden of colorectal cancer
NYK011: Vaccine aimed at reducing the burden of colorectal cancer Nykode Therapeutics | Company Presentation - March 2023 34
Slide 35: Pipeline expansion from pre-cancerous polyps to colorectal cancer
Pipeline expansion aims at addressing patients ranging from high- risk pre-cancerous polyps to colorectal cancer • Colorectal cancer develops from premalignant polyps on the colon or rectum’s mucosal surface • Disease development and screening programs represent an Broad patient population opportuni
Slide 36: Potential first-in-class program with 4th module technology
Potential first-in-class program including Nykode’s 4th module 2nd generation technology • NYK011 is a potential first-in-class oncology vaccine program based on careful selection and novel combination of tumor-associated antigens (TAA) • Leverages Nykode’s expertise to elicit strong and broad CD8 T
Slide 37: Vaccibodies induce potent T cell responses against tolerance-subject targets
Vaccibodies induce potent T cell responses against targets subject to various degrees of central tolerance Potential immunogenicity High thymic expression Low thymic expression No thymic expression Mouse melanocyte genes Mouse MAGE-like genes Mouse PRAME-like genes Nykode Therapeutics | Company Pres
Slide 38: VB10.NEO - Individualized cancer immunotherapy
VB10.NEO- Individualized cancer immunotherapy Nykode Therapeutics | Company Presentation - March 2023 38
Slide 39: Individualized cancer vaccine designed to target a broad range of tumours
Nykode’s individualized cancer vaccine is designed to target a broad range of tumours Vaccine design Key clinical results • APC-targeted vaccine technology leverages targeting unit to enhance CD8+ response ♦ 2 clinical trials in more • Induces immune response in hard-to-treat patients with low TMB t
Slide 40: VB10.NEO programs
VB10.NEO programs Safety clearance of 9 mg dose with no safety concerns and no dose limiting toxicities observed N-01 N-02 r/m Melanoma, non-small cell lung cancer (NSCLC), clear renal cell carcinoma, urothelial Indication r/m cancer, covering more than ten indications cancer or squamous cell carcin
Slide 41: T cell responses to majority of selected neoepitopes
T cell responses to majority of % immunogenic Neoepitopes per patient selected neoepitopes Indication UC All patients across five indications SCCHN 60 51% showed a response to at least one % of neoepitopes neoepitope 35% 40 24% RCC On average, 53% of selected 20 15% 10% neoepitopes were immunogenic,
Slide 42: VB10.NEO amplifies pre-existing and induces novel T-cell responses
VB10.NEO amplifies pre-existing T-cell responses and induces multiple novel T-cell specificities Expansion of pre-existing and induction of novel T cells De novo response Expansion of both pre-existing and novel Amplified response T-cell responses in most patients (at least Indication Stable respons
Slide 43: Majority of neoepitopes activates CD8 T cells
Preliminary immune phenotyping shows that the majority of neoepitopes activates CD8 T cells CD8 T cells response detected Selected patients No CD8 T cells response detected T cell responses are characterized by both CD8 and CD4 T cells 53% 100% 75% 100% 100% 80% The majority of tested 01-001 01-
Slide 44: Multiple vaccinations boost breadth and magnitude of T cell responses
Multiple vaccinations boost the breadth and magnitude of functional T cell responses Patients completing 1-Year of treatment Breadth Magnitude 20 40000 Increase in the breadth and 30000 magnitude of functional T cell responses observed over time. Number of increased neoantigens 15 15000 Stacked SFU/
Slide 45: Vaccine-specific T cells remain functional up to 1 year
Vaccine-specific T cells remain functional and immunogenic up to 1-year after last vaccination VB10.NEO induces a favorable and long-lasting T cell memory phenotype Nykode Therapeutics | Company Presentation - March 2023 45
Slide 46: T cell responses per patient
T cell responses per patient Total T cell responses De novo T cell responses Patients grouped in lower and higher than median immune responses Patients included are overlapping between EFR and FAS (N=32). Nykode Therapeutics | Company Presentation - March 2023 46
Slide 47: VB10.NEO key differentiators
Solid manufacturing chain Safety Safety profile similar to 100% successful checkpoint inhibitor monotherapy vaccine production No increase in immune-related Robust supply chain adverse events NeoSELECT Immune response High fraction of VB10.NEO Induces broad and strong immunogenic neoanti
Slide 48: Autoimmunity and further platform potential
Autoimmunity and further platform potential Nykode Therapeutics | Company Presentation - March 2023 48
Slide 49: Antigen-specific tolerance by targeting epitopes to tolerogenic APCs
Induction of antigen specific tolerance can be achieved by targeting disease causing epitopes to tolerogenic APCs MECHANISM OF ACTION – TOLERANCE INDUCTION (INVERSE VACCINATION) Cells transfected with DNA plasmid vaccine CD4+ Treg Tol APC CD4+ Treg Tol APC Effector T Effector T cell cell 1 Cells enc
Slide 50: Modular design able to ensure antigen-specific immune tolerance
Modular design with multiple targeting and 4th modules able to ensure antigen-specific immune tolerance Module 1: Multiple targeting units for receptors on tolerizing APCs identified including natural ligands and other targeting molecules Module 3: Auto-antigens or allergens known to elicit unwanted
Slide 51: Vaccibodies prevent disease in mouse multiple sclerosis model
Recombinant Vaccibodies targeting tolerogenic DCs prevents serious disease in a mouse model of multiple sclerosis EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS (EAE) MODEL Daily clinical scores Paralysis ✱✱✱ 4 ✱✱ day -7 day -3 day 0 Day 29 80 3 Disease Termination 60 EAE score induction AUC (5-29) 2 40
Slide 52: Dose-dependent decrease in disease associated cytokines
Dose-dependent decrease in disease associated cytokines induced by Nykode’s inverse vaccines, differentiated from Ag alone EAE MODEL Immune parameter read-out at day 15 (at peak of disease) day -7 day -3 day 0 day 15 MOG(35-55) recall assay using splenocytes Disease Termination and ✱✱✱ induction imm
Slide 53: Disease prevention in EAE model via alternative target
Disease prevention in the EAE model can also be achieved by targeting an alternative target on tolerizing APCs EAE MODEL Paralysis VB vaccine TV004 5 ✱✱✱ Untreated 80 35 µg VB vaccine TV004 Targeting unit 1 4 Target 1 60 EAE score AUC (5-29) 3 40 2 20 EAE 1 0 antigen e ed 0 in at cc Tol re 6 8 10 12
Slide 54: DNA vaccination prevents type 1 diabetes in mouse model
DNA vaccination with Vaccibody targeting tolerogenic APCs prevents type 1 diabetes in a spontaneous mice model Type 1 diabetes is an autoimmune disease where the immune system attacks insulin producing cells in the pancreas Day 0 day 7 day 14 The Non-Obese Diabetic (NOD) model is a mouse diabetes mo
Slide 55: Vaccibody induces long-lasting efficacy post treatment
DNA vaccination with Vaccibody induces long-lasting efficacy post treatment Dosing once weekly until week 16 Week 16 of treatment Wk 0 Wk 1 Wk2 Wk 3 Wk 4 Wk 5……… Weekly monitoring Remove treatment Still ongoing 9 wk old mice NOD DIABETES MODEL (ONGOING STUDY) VB vaccine Incidence of of Incidence dia
Slide 56: Business model ready to accelerate development in autoimmune diseases
Nykode’s successful business model validated and ready to accelerate development in autoimmune diseases Expand candidate to all addressable Expansion into the First in patients broad potential of house candidate autoimmune disorders, towards the allergies and organ Clinical market transplantation Po
Slide 57: Tolerance Highlights
Competition Opportunities Autoimmune disease Limited competition within antigen specific tolerance Allergies Organ transplantation Partnership opportunities Medical Need New platform allows product Tolerance High unmet medical need areas specific collaborations Existing therapies are b
Slide 58: mRNA oncology vaccine
mRNA oncology vaccine Nykode Therapeutics | Company Presentation - March 2023 58
Slide 59: APC targeting technology can leverage mRNA vaccines
Nykode’s APC targeting technology can leverage mRNA vaccines and presents opportunity for platform expansion Targeted delivery via APCs using Nykode’s technology has been shown to induce broader and stronger CD8+ immune responses vs. existing ‘antigen-alone’ approaches. Preclinical studies have demo
Slide 60: APC-targeted technology offers improvement of mRNA vaccines
Nykode’s APC-targeted technology offers improvement of mRNA based vaccines Stronger T cell responses to a wider variety of MC38 T cell epitopes Prime vaccination only (D14) Prime + boost vaccination (D28) ✱ p=0.0473 ✱ p=0.0192 25000 2000 N01 N01 N02 N02 N03 N03 N04 N04 20000 N05 N05 1500 N06 N06 N07
Slide 61: Strong responses driven by broad CD8 T cell specificity
The strong responses by Nykode’s APC-targeted technology is primarily driven by broad CD8 T cell specificity The strong responses by Nykode’s vaccine are primarily CD8 driven and includes both effector and memory subtypes Nykode pDNA vs Ag mRNA Nykode mRNA vs Ag mRNA Nykode pDNA mRNA-Ag 80μg 5μg 800
Slide 62: Unlocking the full potential of cancer vaccines
Unlocking the full potential of cancer vaccines Nykode Therapeutics | Company Presentation - March 2023 62
Slide 63: Dedicated to a sustainable cancer vaccine platform
Nykode is dedicated to fill the gaps and offer a sustainable cancer vaccine platform CONTROL OF WHICH CELLS THAT TAKE UP THEANTIGEN AND HOW IT IS PRESENTED TO T CELLS THROUGHAPC-TARGETING Superior immunogenicity • Broad response to multiple epitopes and reduced risk of tumor escape • Proven abilit
Slide 64: Future offering all cancer patients a vaccine at diagnosis
Unlocking possibilities for a future offering all cancer patients a vaccine at diagnosis Exploring the full range of cancer antigens INDIVIDUALIZED OFF-THE-SHELF Viral Antigens Tumor-specific Tumor-associated Neoantigens Antigens VB10.16 Undisclosed Undisclosed VB10.NEO Future in house and partnered
Slide 65: Modular platform designed to unlock multiple applications
Nykode’s modular platform is designed to unlock multiple applications across targets and therapeutic areas APC-specific Ag delivery and stimulation Expanded use of modularity Infectious Building Novel Cancer disease additional combinations and immunotherapies immunotherapies modules structures Immun
Slide 66: Financial overview & outlook
Financial overview & outlook Nykode Therapeutics | Company Presentation - March 2023 66
Slide 67: Upcoming milestones
Upcoming milestones Q1 ‘24 VB10.16 Initiate potentially registrational VB-C-04 trial in the U.S. in patients with Cervical Cancer recurrent/metastatic disease and PD-L1 positive tumors VB10.16 Q1 ‘24 Cervical Cancer Updated survival data from VB-C-02 Phase 2 trial Oncology H2 ‘24 VB10.16 Recommended
Slide 68: Our conviction in Nykode's platform has never been stronger
Our conviction in Nykode’s platform has never been stronger Differentiated APC targeting immunotherapy platform validated and de-risked through clinical data and top tier US biopharma partnerships Clinical durability and survival data further supported today by long lasting immune response with both
Slide 69: Unlocking the future of medicine
UNLOCKING THE FUTURE OF MEDICINE Contact: Alexandra Deschner Head of Investor Relations [email protected] Nykode Therapeutics | Company Presentation - March 2023
Slide 70: VB-C-01
VB-C-01
Slide 71: VB C-01: First trial with VB10.16 as monotherapy in precancerous lesions
VB C-01: First trial with VB10.16 as monotherapy for treatment of HPV16+ precancerous lesions VB C-01 Exploratory, open labelled, multi-centre study in patients with HPV16+ High Grade Cervical Intraepithelial Neoplasia (HSIL, CIN 2/3) Dosing phase (3mg per dose) Expansion phase 8 patients Cohort 1:
Slide 72: VB10.16: Correlation of immune response and lesion size reduction
VB10.16: Strong correlation with strength of induced HPV16- specific immune response and lesion size reduction 13 of 14 patients showed COHORT 1: COHORT 2: LESION SIZE REGRESSION increased T cell responses 0 – 3 – 6 WEEKS 0 – 4 – 12 WEEKS CORRELATES WITH STRONG after vaccination with HPV-16 SPECIF
Slide 73: VB10.16: homologous booster dose induced strong T cell responses
VB10.16: homologous booster dose induced strong T cell responses in all patients in the expansion cohort HOMOLOGOUS BOOST ENSURE STRONG AND LONG-LASTING T STRONG HPV16-SPECIFIC T CELL REPSONSES IN ALL CELL RESPONSE PATIENTS IN THE EXPANSION COHORT The vaccination regimen from cohort 1 (Q3W) plus a
Slide 74: VB10.16: significant correlation of T cell responses and lesion size
VB10.16: highly significant correlation between vaccine induced HPV16-specific T cell responses and lesion size across all cohorts LESION SIZE REGRESSION SIGNIFICANT CORRELATION OBSERVED WITH % LESION SIZE REDUCTION AND CORRELATES WITH HPV-16 SPECIFIC # SFU/MILL RESPONSES • Cohort 1 • Cohort 2 • Exp
Slide 75: Promising clinical data as monotherapy in pre-cancerous lesions
Promising clinical data as monotherapy in pre-cancerous lesions Lesion size reduction observed in majority of subjects (16 of 17) in the Expansion cohort CIN regression to CIN1 or no CIN in 10 subjects HPV16 and/or p16 clearance in 8 subjects Upregulation of PD-L1 in lesions post-vaccination
Slide 76: VB-C-03
VB-C-03
Slide 77: VB-C-03 trial in advanced HPV16+ HNSCC
VB-C-03 trial in advanced HPV16+ HNSCC Combination treatment of VB10.16+pembrolizumab* in 1L HPV16+ R/M HNSCC Dose-escalation (Phase 1) with randomized dose-expansion (Phase 2a) trial ♦ Key eligibility criteria ♦ Dosing schedule VB10.16 vaccine ♦ Recommended Phase 2 set (RP2S): Randomization (1:2) o
Slide 78: VB-C-03 Clinical trial design
VB-C-03 Clinical trial design Combination treatment of VB10.16+pembrolizumab in 1L HPV16+ R/M HNSCC Phase 1 Dose escalation phase Phase 2a Dose expansion phase 9 9m 9 mg g mg Cohort A: RP2D* Interim analysis OBD** Final analysis No DLT RP2S VB10.16 9 9 9 mg mg mg VB10.16 dosing R No DLT 6 6 6 DLT 6
Nykode Therapeutics — Investor Presentation (March 2024) on 6ix